Successful closing: Syntegon and Telstar officially join forces

05-Nov-2024

Following regulatory approval, Syntegon and Azbil Corporation have officially closed the acquisition of Telstar by Syntegon. The Telstar workforce will now join the Syntegon team in the Pharma Liquid Business Unit. With the joint offering of fill-finish equipment, isolator systems, freeze-dryers, loading and unloading systems as well as further upstream and downstream equipment, customers now have access to a seamless technology and service portfolio for the production of antibiotics, vaccines, or biologics.

Syntegon

From left to right: Stephan März (Executive VP Pharma Liquid, Syntegon), Pilar Ramirez (General Counsel, Telstar), Torsten Türling (CEO, Syntegon), Jordi Serrat (Technology & Operations Corporate Manager, Telstar), Jordi Puig (Managing Director, Telstar), Petros Kapelles (Chief Operations Officer, Syntegon), Emili Pablos (Executive VP & Chief Financial Officer, Telstar), Matthias Wagner (Managing Director, Telstar).

Strengthening strategic growth

“Syntegon is world market leader in liquid vial filling and isolator systems. Together with Telstar, we will further enhance our portfolio of innovative technologies and sustainable solutions, strengthen our strategic growth, and expand our global reach,” says Torsten Türling, CEO of the Syntegon Group. “We received highly positive customer feedback and several inquiries for our joint offering following the acquisition announcement in June. This clearly shows that we are on the right track to becoming the go-to partner for seamless solutions from a single source.”

Leveraging joint expertise

“We are very much looking forward to leveraging our joint expertise for the benefits of our existing and new customers,” says Jordi Puig, Managing Director of Telstar. “By using the synergies of a strong team, we can offer truly seamless line solutions and streamlined processes with one face to the customer. This way, we will support them even better in achieving long-term stability of their pharmaceuticals and fast time to market.”

Telstar, headquartered in Terrassa (Barcelona), Spain, has four production plants, six technology centers and ten consultancy and engineering services centers, and commercial offices all over the world. By combining these capabilities with Syntegon’s global reach, both companies are now in an even better position to offer both pharmaceutical manufacturers and Contract Manufacturing Organizations (CMOs) complete line solutions. Moreover, the joint service network will be expanded significantly, adding geographical coverage, proximity, and application expertise.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance